Marshall Wace’s Centessa Pharmaceuticals CNTA Stock Holding History

Marshall Wace’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-168,177	Closed	-$6.68M	–	3238
2026 Q1	$6.68M	Sell	168,177 -47,953	-22%	-$1.23M	0.01%	1159
2025 Q4	$5.41M	Buy	216,130 +102,540	+90%	+$2.6M	﹤0.01%	1116
2025 Q3	$2.75M	Sell	113,590 -229,728	-67%	-$4.08M	﹤0.01%	1466
2025 Q2	$4.51M	Buy	343,318 +207,291	+152%	+$2.63M	0.01%	1191
2025 Q1	$1.96M	Sell	136,027 -3,705	-3%	-$60.6K	﹤0.01%	1473
2024 Q4	$2.34M	Sell	139,732 -41,121	-23%	-$681K	﹤0.01%	1370
2024 Q3	$2.89M	Sell	180,853 -44,095	-20%	-$540K	﹤0.01%	1228
2024 Q2	$2.03M	Sell	224,948 -6,617	-3%	-$62.8K	﹤0.01%	1367
2024 Q1	$2.62M	Buy	+231,565	New	+$2.19M	﹤0.01%	1239

Marshall Wace's CNTA Position: Q2 2026 in Review

Marshall Wace sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 168,177 shares — an estimated $6.68M sold.

Marshall Wace first reported a position in CNTA in Q1 2024 and held it in 9 quarters. The position peaked at $6.68M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Marshall Wace reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Marshall Wace sold 168,177 Centessa Pharmaceuticals shares in Q2 2026, an estimated $6.68M.
Marshall Wace first reported a position in Centessa Pharmaceuticals in Q1 2024 and held it in 9 quarters.
Marshall Wace's Centessa Pharmaceuticals position peaked at $6.68M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.